निराशा भरे माहौल में खुशखबरी कोरोना की नई दवा कॉकटेल मेदांता हॉस्पिटल गुड़गांव में आ गई डॉ Trehan चेयरमैन मेदांता हॉस्पिटल गुड़गांव

BK Sood :senior executive editor

The cocktail drug works when given timely — that is in the first seven days of the viral replication stage or when the virus multiplies. The FDA-approved drug cocktail therapy reduces hospitalisation and death in COVID-19 patients by 70 percent.

L

India has begun administering antibody cocktails to COVID-19 patients. On May 26, an 84-year-old Haryana man became the first coronavirus patient to receive the COVID-19 drug cocktail, which gained popularity after it was used to treat former United States President Donald Trump.

Roche’s antibody cocktail, which is available in India, comprises the drugs Casirivimab and Imdevimab. Casirivimab and Imdevimab are human immunoglobulin G-1 (IgG1) monoclonal antibodies, which are proteins that mimic the immune system’s ability to fight off harmful pathogens. Casirivimab and Imdevimab are specifically designed to block the coronavirus’ attachment and entry into human cells.

In an interview to ABP news channel today at 1 p.m. Dr Trehan the the chairman of Medanta Hospital said that this treatment has started in Medanta hospitals and it will be available in other Hospital very soon the news is very positive and favourable from Indian point of view. But still after the treatment one has to be very careful and follow the covid protocols.